H.C. Wainwright Keeps Their Buy Rating on Aslan Pharmaceuticals (ASLN)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals (ASLNResearch Report), with a price target of $7.00. The company’s shares closed last Friday at $0.85.

Chen covers the Healthcare sector, focusing on stocks such as Prophase Labs, Veru, and Co-Diagnostics. According to TipRanks, Chen has an average return of -6.7% and a 36.07% success rate on recommended stocks.

Currently, the analyst consensus on Aslan Pharmaceuticals is a Moderate Buy with an average price target of $5.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $3.36 and a one-year low of $0.36. Currently, Aslan Pharmaceuticals has an average volume of 256K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm’s portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Read More on ASLN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More